深圳商报·读创客户端驻穗记者 姚嘉莉 当前，广东消费品以旧换新"国补"活动与"粤享暖冬 乐游广东"消费季持续升温。1月8日，广州白马服 装市场迎来第三十三个生日庆典，将陆续推出的年终大促、品牌快闪市集、33周年庆、采购商答谢沙 龙、内购会等系列活动。这不仅仅是一家老牌专业市场对自身生日的庆祝，更是深度融入广东促消费大 潮的实干行动，为大湾区消费市场注入持续暖意。 老牌商贸龙头焕发新活力 在白马生日之际，广州白马特邀全年紧密合作的专业采购商伙伴及采购商团长，共聚采购商答谢沙龙， 进一步深化B端采购商与白马之间的情感连接与合作互信。为了让采购更加顺畅高效，白马向采购商朋 友们介绍多重采批福利与2026年度白马的核心动态，助力采购商省心省力对接优质资源，优化采购体 验。同期举办的内购会，旨在通过独家折扣、专属导购等权益，强化与零售端核心客户的粘性，刺激春 节前采购高峰，实现以精准服务推动消费落地。 三十三年栉风沐雨，白马始终与广州专业市场同频共振，亲历其辉煌征程，亦伴其转型蝶变。以"深化 客户价值"为核心，白马打造系列主题活动，构建起 "文化引流、政策赋能、服务增效"的消费生态体 系。通过强化市场方、品牌商、采购商 ...

12月18日，开开实业涨6.36%，截至发稿，报15.04元/股，成交1.23亿元，换手率5.28%，总市值39.50亿 元。 资料显示，上海开开实业股份有限公司位于上海市静安区昌平路678号一楼，成立日期1997年8月4日， 上市日期2001年2月28日，公司主营业务涉及以中医药流通、中医药学服务(中医问诊服务)和服装批 发、零售为主营业务。主营业务收入构成为：批发类74.48%，零售类18.18%，卫生服务类4.42%，租赁 类1.77%，其他1.14%。 从开开实业十大流通股东角度 数据显示，汇添富基金旗下1只基金位居开开实业十大流通股东。中证上海国企ETF（510810）三季度 减持16.42万股，持有股数78.75万股，占流通股的比例为0.33%。根据测算，今日浮盈赚取约70.87万 元。 中证上海国企ETF（510810）成立日期2016年7月28日，最新规模79.94亿。今年以来收益6.03%，同类 排名3694/4197；近一年收益6.03%，同类排名3554/4143；成立以来收益2.85%。 中证上海国企ETF（510810）基金经理为吴振翔。 截至发稿，吴振翔累计任职时间15年320天， ...

Core Viewpoint - The company, Kaikai Industrial (600272), primarily operates in the fields of traditional Chinese medicine distribution, Chinese medicine services, and clothing wholesale and retail, with a focus on health services and branded apparel [1] Business Segments - The pharmaceutical segment mainly involves wholesale and retail of both traditional and Western medicines, medical devices, reagents, consumables, and diagnostic services [1] - The clothing segment focuses on the wholesale and retail of the "Kaikai" brand shirts, woolen sweaters, and other apparel, as well as customized workwear group purchases [1] - Currently, the company's main business operations are located in the Jing'an District of Shanghai, with no business activities in Taiwan [1]

Core Viewpoint - The company, Shanghai Kaikai Industrial Co., Ltd., has reported a mixed financial performance for 2024, with revenue growth driven by its SPD business, but a decline in net profit, alongside plans for a new share issuance to strengthen its capital base [3][4][6]. Company Announcements - The 2024 annual general meeting is scheduled for May 23, 2025, to discuss various reports and proposals, including financial results and a cash dividend plan [3][6]. - The company achieved a revenue of 1,093.92 million yuan in 2024, marking an 18.25% year-on-year increase, primarily due to significant growth in the SPD business [4][6]. - The net profit attributable to the parent company was 34.99 million yuan, reflecting a 10.94% year-on-year decrease [4][6]. - A cash dividend of 0.044 yuan per share is proposed, totaling 10.69 million yuan, which represents 30.55% of the net profit for the year [4][5]. Performance Highlights - The company has maintained a consistent cash dividend policy for 12 years, with a payout ratio exceeding 30% [4][5]. - The retail sector in China saw a total retail sales of consumer goods reaching 48.8 trillion yuan in 2024, with a growth rate of 3.5%, indicating a slowdown compared to the previous year [5]. Institutional Research Insights - During a recent performance briefing, the company emphasized its commitment to the "big health" industry transformation and its strategic focus on enhancing the pharmaceutical and apparel sectors [5]. - The company plans to issue 19,651,945 shares at a price of 8.13 yuan per share, aiming to raise up to 159.77 million yuan for working capital [6][8]. - Following the issuance, the controlling shareholder's stake will increase from 26.51% to 32.00%, with the local state-owned assets supervision authority remaining the actual controller [6][8].